BioNTech SE ADR (BNTX) News
Filter BNTX News Items
BNTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNTX News Highlights
- For BNTX, its 30 day story count is now at 95.
- Over the past 29 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- The most mentioned tickers in articles about BNTX are SE, MRNA and PFE.
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
BioNTech down 9% following Israeli fourth COVID jab study on OmicronShares of BioNTech (BNTX -7.8%) have fallen this morning following results from an Israeli study showing that a fourth COVID-19 shot is less effective against the Omicron variant than prior strains. "We see an increase in antibodies, higher than after the third dose," said lead researcher Gili Regev-Yochay. "However, we see... |
This New Study Suggests Pfizer, BioNTech Are Losing The Omicron BattleA fourth dose of Pfizer and BioNTech''s Covid shot is only partly effective against omicron, according to a new test. The vaccine stocks fell. |
Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling TodayShares of vaccine makers, including Moderna Inc Full story available on Benzinga.com |
The Right Bet On BioNTech SENo summary available. |
Omicron: Why a fourth dose of coronavirus vaccines may not be 'absolutely necessary,' doctor saysDr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions. |
Top Biotech Stocks for Q1 2022The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline. |
Pendal Group Ltd Buys NXP Semiconductors NV, Ferguson PLC, Unilever PLC, Sells Philip Morris ...Investment company Pendal Group Ltd (Current Portfolio) buys NXP Semiconductors NV, Ferguson PLC, Unilever PLC, Taiwan Semiconductor Manufacturing Co, BioNTech SE, sells Philip Morris International Inc, Progressive Corp, Exelon Corp, Atmos Energy Corp, Sempra Energy during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pendal Group Ltd. |
UPDATE 1-EU watchdog urges vaccine developers not to focus only on OmicronThe European Union drugs regulator said pharmaceuticals companies should work on more than one upgraded COVID-19 shot, not only tailored to the fast-emerging Omicron variant but also versions that address a combination of variants. "What we are hearing from other regulatory agencies also is that it is important not to exclude any options," the European Medicines Agency's head of vaccines strategy, Marco Cavaleri, told a media briefing on Tuesday. Vaccine makers working on a redesign of their established shots to address Omicron, which is crowding out the Delta variant in many regions of the world, include BioNTech-Pfizer , Moderna and the alliance between AstraZeneca and Oxford University. |
Preliminary Israeli study shows fourth COVID booster doesn’t stop omicron infectionsA fourth vaccine boost lifted antibodies, but omicron infections persisted, according to an unpublished study at an Israeli hospital |
NVAX Stock Alert: Why Is Novavax Plunging Today?With the vaccine mandate failing to pass, companies like Novavax face an uncertain future. |